REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Purpose: To study the real-world outcomes of intravitreal faricimab (IVF) in long-standing neovascular age-related macular degeneration (nAMD) over a 1-year study period. Methods: Retrospective single-center cohort study of patients with previously treated nAMD receiving IVF with at least 12 months of follow-up. Main outcome measures include injection intervals, visual acuity (VA), and optical coherence tomography features. Results: A total of 263 eyes from 217 patients received 6.4 +/- 2.3 IVF injections over 1 year. Injection interval increased after switching to IVF (5.9 +/- 1.8 vs. 7.6 +/- 2.4 weeks) (P < 0.01). There was no improvement in VA after switching to IVF at any time period (P > 0.15). Average CST decreased after the first IVF injection and was sustained for 1 year (313.7 +/- 96.0 vs. 288.2 +/- 80.6 mu m) (P < 0.01). There was a statistically significant resolution of subretinal fluid but not IRF at all time points (40.8%-50.4%; P < 0.01). Persistent fluid after the first IVF injection was resolved in 34.4% (n = 45) by 1 year. IVF was discontinued in 31 eyes (11.8%), four (1.6%) that experienced intraocular inflammation. Conclusion: Long-standing nAMD eyes switched to IVF experienced a significant extension in injection interval, stable visual acuity, improvement in CST, and resolution of fluid on OCT in many patients over 1 year.